56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results. (January 2016) - Gettinger, S.N.; Bazhenova, L.A.; Salgia, R.; Langer, C.J.; Gold, K.; Rosell, R.; Shaw, A.T.; Weiss, G.J.; Dorer, D.J.; Rivera, V.M.; Kerstein, D.; Camidge, D.R.